Detail akcie AdaptimmTher Sp ADR online

Business Summary: Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Adaptimmune Therapeutics PLC - ADR revenues increased from $52.7M to $133.9M. Net income totaled $21M vs. loss of $20.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects General and administrative - other decrease of 48% to $7.3M (expense), Restructuring charges decrease from $1.7M (expense) to $0K.